IMMUNOGENICITY IN MACAQUES OF A DNA/OLIGOMERIC ENVELOPE PROTEIN HIV VACCINE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究旨在评估用聚乳酸-乙醇酸酯（PLG）微粒配制的临床级DNA和使用DNA/PLG初始蛋白增强方案的临床级重组Env蛋白HIV疫苗。该研究的第二个目标是比较mulatta和束状分枝杆菌的免疫反应。在第0、4和8周给猕猴接种表达HIV-1 gag和env的质粒dna。质粒采用阳离子PLG微粒配制。重组HIV gp140env蛋白与等体积的MF-59佐剂混合，在第24、36和48周肌肉注射加强疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was designed to evaluate clinical-grade DNA formulated with polylactide-coglycolide (PLG) microparticles and clinical-grade, recombinant Env protein vaccines for HIV using a DNA/PLG prime protein boost regimen. A secondary goal of the study was to compare the immune responses of M. mulatta and M. fascicularis. Macaques were vaccinated at weeks 0, 4, and 8 with plasmid DNAs expressing HIV-1 gag and env. Plasmids were formulated with cationic PLG microparticles. Booster vaccinations with recombinant HIV gp140env protein mixed with an equal volume of MF-59 adjuvant were given intramuscularly at weeks 24, 36 and 48.